Treatment outcomes of pediatric acute myeloid leukemia: a retrospective analysis from 1996 to 2019 in Taiwan

Yung Li Yang, Tang Her Jaing, Shih Hsiang Chen, Hsi Che Liu, Iou Jih Hung, Dong Tsamn Lin, Chao Ping Yang, Ching Tien Peng, Kai Hsin Lin, Chih Cheng Hsiao, Shiann Tarng Jou, Jiann Shiuh Chen, Ming Tsan Lin, Shih Chung Wang, Te Kau Chang, Fang Liang Huang, Chao Neng Cheng, Kang Hsi Wu, Jiunn Ming Sheen, Shu Huey ChenMeng Yao Lu, Giun Yi Hung, Hsiu Ju Yen, Yuh Lin Hsieh, Jinn Li Wang, Yu Hsiang Chang, Hsiu Hao Chang, Ting Chi Yeh, Te Fu Weng, Jen Yin Hou, Bow Wen Chen, Rong Long Chen, Lin Yen Wang, Wan Ling Ho, Yu Chieh Chen, Shin Nan Cheng, Yu Hua Chao, Shang Hsien Yang, Ting Huan Huang, Shu Wei Chou, Chien Yu Lin, Hsuan Yu Chen, Yu Mei Y. Chao, Der Cherng Liang, Tai Tsung Chang

研究成果: 雜誌貢獻文章同行評審

摘要

Improvement in outcomes of children with acute myeloid leukemia (AML) is attributed to several refinements in clinical management. We evaluated treatment outcomes of Taiwanese pediatric AML patients in the past 20 years. Overall, 860 de novo AML patients aged 0–18 years and registered in the Childhood Cancer Foundation of R.O.C during January 1996–December 2019 were included. Survival analysis was performed to identify factors that improved treatment outcomes. Regardless of treatment modalities used, patients during 2008–2019 had better 5-year event-free survival (EFS) and overall survival (OS) rates than patients during 1996–2007. For patients received the TPOG-AML-97A treatment, only 5-year OS rates were significantly different between patients diagnosed before and after 2008. Patients with RUNX1–RUNX1T1 had similar relapse-free survival rates, but 5-year OS rates were better during 2008–2019. However, the survival of patients who received hematopoietic stem-cell transplantations (HSCT) did not differ significantly before and after 2008. For patients without relapse, the 5-year OS improved during 2008–2019. Non-relapse mortality decreased annually, and cumulative relapse rates were similar. In conclusion, 5-year EFS and OS rates improved during 2008–2019, though intensities of chemotherapy treatments were similar before and after 2008. Non-relapse mortality decreased gradually. Further treatment strategies including more intensive chemotherapy, novel agents’ use, identification of high-risk patients using genotyping and minimal residual disease, early intervention of HSCT, and antibiotic prophylaxis can be considered for future clinical protocol designs in Taiwan.
原文英語
文章編號5893
期刊Scientific Reports
11
發行號1
DOIs
出版狀態已發佈 - 十二月 2021

ASJC Scopus subject areas

  • 多學科

指紋

深入研究「Treatment outcomes of pediatric acute myeloid leukemia: a retrospective analysis from 1996 to 2019 in Taiwan」主題。共同形成了獨特的指紋。

引用此